Last updated: April 19, 2026

Application No. 18/282,507

ANTI-VACCINIA VIRUS ANTIGEN ANTIBODIES AND RELATED COMPOSITIONS AND METHODS

Non-Final OA

Filed

Sep 15, 2023

Examiner

HADDAD, MAHER M

Art Unit

1641

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

UVIC INDUSTRY PARTNERSHIPS INC.

OA Round

1 (Non-Final)

This examiner grants 50% of cases after interview

— +54.2% interview lift. A telephonic interview to clarify the technical implementation could significantly improve the outcome.

Based on 1042 resolved cases, 2023–2026

Examiner Intelligence

HADDAD, MAHER M View full profile →

Grants 50% of resolved cases

Career Allow Rate

525 granted / 1042 resolved

-9.6% vs TC avg

Strong +54% interview lift

Without

With

+54.2%

Interview Lift

resolved cases with interview

Typical timeline

3y 1m

Avg Prosecution

51 currently pending

Career history

1093

Total Applications

across all art units

Statute-Specific Performance

§101

0.7%

-39.3% vs TC avg

§103

38.8%

-1.2% vs TC avg

§102

10.8%

-29.2% vs TC avg

§112

15.1%

-24.9% vs TC avg

Black line = Tech Center average estimate • Based on career data from 1042 resolved cases

Prosecution Timeline

Sep 15, 2023

Application Filed

Mar 03, 2026

Non-Final Rejection (current)

Precedent Cases

Applications granted by this same examiner with similar technology

19/065,094

Patent 12600770

ANTIBODIES TO CONNECTIVE TISSUE GROWTH FACTOR (CTGF) AND USES THEREOF

2y 5m to grant Granted Apr 14, 2026

18/015,690

Patent 12590166

CD20 BINDING MOLECULES AND USES THEREOF

2y 5m to grant Granted Mar 31, 2026

18/355,975

Patent 12590157

METHODS OF TREATING GASTROINTESTINAL IMMUNE-RELATED ADVERSE EVENTS IN IMMUNE ONCOLOGY TREATMENTS

2y 5m to grant Granted Mar 31, 2026

18/479,371

Patent 12590144

CARDIAC TROPONIN I SPECIFIC ANTIBODY, KIT AND USES THEREOF

2y 5m to grant Granted Mar 31, 2026

18/247,653

Patent 12577310

CANINIZED ANTIBODIES TO CANINE INTERLEUKIN-31 RECEPTOR ALPHA

2y 5m to grant Granted Mar 17, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.

Prosecution Projections

1-2

Expected OA Rounds

50%

Grant Probability

99%

With Interview (+54.2%)

3y 1m

Median Time to Grant

Low

PTA Risk

Based on 1042 resolved cases by this examiner. Grant probability derived from career allow rate.

ANTI-VACCINIA VIRUS ANTIGEN ANTIBODIES AND RELATED COMPOSITIONS AND METHODS

This examiner grants 50% of cases after interview

Examiner Intelligence

Statute-Specific Performance

Prosecution Timeline

Precedent Cases

Applications granted by this same examiner with similar technology

AI Strategy Recommendation

Prosecution Projections

Ready to respond to this office action?

Sign in with your work email